Konjac supplement alleviated hypercholesterolemia
and hyperglycemia in type 2 diabetic subjects--a randomized double-blind
J Am Coll Nutr. 2003 Feb;22(1):36-42.
Chen HL, Sheu WH, Tai TS, Liaw YP, Chen YC.
Institute of Nutritional Science, School of Nutrition, Taichung, Taiwan,
The present study was designed to evaluate effects of konjac glucomannan
(KGM) supplement (3.6 g/day) for 28 days on blood lipid and glucose
levels in hyperlipidemic type 2 diabetic patients and the possible mechanism
for the reductions in blood lipid levels.
Twenty-two diabetic subjects (age 64.2 + 8.4 years, BMI 25.5 + 3.2 kg/m(2))
with elevated blood cholesterol levels (fasting glucose between 6.7-14.4
mmol/L), but currently not taking lipid-lowering medication, were recruited
to participate in a two 28-day period, randomized, double-blind, crossover
clinical trial. Fasting blood samples drawn on the initial and final
days of each period were determined for plasma lipids and glucose levels.
Feces collected at the end of each experimental period were analyzed
for neutral sterol and bile acid contents.
Compared with placebo, KGM effectively reduced plasma cholesterol (11.1%,
p = 0.0001, adjusted alpha = 0.006), LDL-cholesterol (20.7%, p = 0.0004,
adjusted alpha = 0.006), total/HDL cholesterol ratio (15.6%, p = 0.0005,
adjusted alpha = 0.007), ApoB (12.9%, p = 0.0001, adjusted alpha = 0.006)
and fasting glucose (23.2%, p = 0.002, adjusted alpha = 0.008). Plasma
triglyceride, HDL-cholesterol, LDL/HDL cholesterol, postprandial glucose
and body weight were not significant after adjustment by the Bonferroni-Hochberg
procedure. Fecal neutral sterol and bile acid concentrations were increased
by 18.0% (p = 0.004) and 75.4% (p < 0.001), respectively, with KGM
The KGM supplement improved blood lipid levels by enhancing fecal excretion
of neutral sterol and bile acid and alleviated the elevated glucose
levels in diabetic subjects. KGM could be an adjunct for the treatment
of hyperlipidemic diabetic subjects.
Randomized Controlled Trial